Website Search
ID 15042

The first day of clinical trials for Gleevec, Bud and Yvonne

Interviewee: Bud. Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998. (DNAi Location: Applications > Genes and medicine > drug design > Bud's Story > The first patient)
Yvonne: Now this is the very first day – fact is it's June of '98. I don't have the exact date, is when the clinical trials started and Bud was the first patient to take this and it was 25 milligrams. And there is a picture that was taken of him and Dr. Druker wishing him luck so we're pretty proud of that picture. And then this guy over here, he's showing you what the pill looks like so at that time it was a number but now it's known at Gleevec™. Bud: Yeah STI-571.
chronic myeloid leukemia,sti 571,brian druker,gleevec,location applications,dnai,romine,cml,interviewee,milligrams,yvonne,clinical trials,leukemia,bud,genes,medicine
Creative Commons License This work by Cold Spring Harbor Laboratory is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.

Related content:

15712. Bud and Yvonne
Bud and Yvonne are delighted by Bud's recovery thanks to Gleevec
15043. Bloodcount returns to normal with Gleevec, Bud and Yvonne
CML causes an increased production of white blood cells. Bud and Yvonne talk about the breakthrough that brought Bud's white blood cell count back to normal.
15041. Getting the diagnosis of chronic myeloid leukemia, Bud
Bud recounts receiving the diagnosis that he had chronic myeloid leukemia.
15056. Approval for Gleevec in record time, Brian Druker
Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.
15057. Before and after Gleevec, Brian Druker
Brian Druker talks about the drug he developed as a turning point in the war on cancer.
16105. The magic pills, Bud and Yvonne
Yvonne talks about the magic pills Bud took.
15058. The first clinical success with Gleevec, Brian Druker
Brian Druker talks about Bud, the first patient restored to health by Gleevec™.
15054. Restoring hope with Gleevec, Brian Druker
Brian Druker talks about how Gleevec has restored patients' hope for the future.
15082. Shutting down cancer with Gleevec, Brian Druker
Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
15055. Using DNA science to control CML, Brian Druker
Brian Druker talks about how the drug he designed targets the molecular cause of CML.
Cold Spring Harbor Laboratory
CSHL HomeAbout CSHLResearchEducationPublic EventsNewsstandPartner With UsGiving